Individuals who suffer from symptoms of gastrointestinal, autoimmune, dermatological and pain conditions make up 80% of the patient population. The good news? Low-dose naltrexone (LDN) has been studied recently in many conditions. Please join us for a free, live webinar that will provide insight into the science, physiology and mechanisms of action of LDN, and answer your questions about the many conditions it may be beneficial for, including:
- Hashimoto’s thyroiditis
- Multiple sclerosis
- Eosinophilic esophagitis
- Crohn’s disease
- Ulcerative colitis
- Inflammatory conditions of the skin
- And more
A live Q&A with the speaker is included.
Sebastian Denison, RPh, FAARM (candidate) │ PCCA Clinical Compounding Pharmacist
Sebastian received his Bachelor of Science in pharmacy at the University of British Columbia. He worked at Northmount Pharmacy in North Vancouver for 11 years, specializing in HRT, veterinary, pain and sports compounding. He also was the manager of Pharmacy Operations with the 2010 Vancouver Winter Olympic/Paralympic Games, and then the manager of the Whistler Olympic Village Polyclinic Pharmacy. In addition to his role as a PCCA clinical compounding pharmacist, Sebastian works with both the U.S. and Canadian CORE compounding training education teams and the pharmacy student education team. Sebastian also speaks at physician, pharmacist and other health care professional education symposiums and events. He has recently lectured for the American Academy of Anti-Aging Medicine on Nutrition and Pain, Pharmacy Compounding and Collaborative Practice, and Alternative Uses for Naltrexone. Sebastian is currently completing the Metabolic Medical Institute’s Fellowship in Metabolic & Nutritional Medicine Fellowship.